Henrik Blou, Gubra CEO
Danish biotech Gubra touts early weight loss data in hot amylin field
The amylin field is heating up ahead of Novo Nordisk’s much-anticipated CagriSema readout later this year.
On Wednesday, Gubra said people …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
